CASI Pharmeceuticals

Management Team

CASI’s senior management team is responsible for aligning the company’s business strategy with its core scientific strengths, while maintaining prudent resource management, fiscal responsibility and accountability.

Ken K. Ren, Ph.D. Dr. Ren joined CASI Pharmaceuticals in April 2012 as interim Chief Executive Officer, and after successful completion of the one-year interim period, was appointed Chief Executive Officer in April 2013, and in December 2014 was elected to the Board of Directors. Prior to joining CASI Pharmaceuticals from 2005-2012, Dr. Ren was the president of Accelovance (China), a subsidiary of Accelovance, Inc., which is a Maryland-based contract research organization. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong. He was a co-founder of the China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology which provided consulting services to health-care and pharmaceutical companies in both the U.S. and China. Over the past 15 years Dr. Ren has been involved in several U.S./China based start-up companies in pharmaceutical development or services. Dr. Ren was a research scientist at Pfizer from 1993–1995 and a Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. from State University of New York at Buffalo in 1990.

Alexander A. Zukiwski, M.D. Dr. Zukiwski joined CASI Pharmaceuticals in April 2017 as Chief Medical Officer. Prior to joining CASI Pharmaceuticals Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics and has been a Director of Arno Therapeutics since 2014. At Arno his responsibilities included leading the clinical development and regulatory affairs teams to support the company’s pipeline of cancer therapies. Prior to Arno in 2007, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson’s (J&J,) medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD); Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. Dr. Zukiwski has more than 15 years of experience in global oncology drug development and supported the clinical evaluation and registration of many successful therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis®, and Doxil®. He serves as a Member of Medical Advisory Board at Gem Pharmaceuticals, LLC and served as a Director of Ambit Biosciences Corporation. Dr. Zukiwski holds a bachelor’s degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.

Cynthia W. Hu, JD. Ms. Hu joined CASI Pharmaceuticals in June 2006 as Vice President, General Counsel & Secretary, and in December 2008 was appointed Chief Operating Officer. Prior to joining CASI Pharmaceuticals, from January 2000 to May 2006, Ms. Hu served as senior attorney for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate and financing matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu served as corporate and securities counsel for a NYSE-listed financial institution and prior to that was in private practice with increasing levels of responsibilities, including at Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on corporate transactions and compliance with corporate and securities laws.

Sara B. Capitelli, CPA Ms. Capitelli joined CASI Pharmaceuticals in January 2011 as Vice President, Finance and Principal Accounting Officer. Prior to joining CASI Pharmaceuticals, from May 2010 to January 2011, Ms. Capitelli served as Controller for the Association for Financial Professionals in Bethesda, Maryland. From 1999-2008, Ms. Capitelli served as Senior Manager with Ernst & Young, where she provided audit and consulting services for small and large public and private companies. Prior to that, she served as Director, Financial Planning and Reporting of Cable & Wireless USA, a wholly-owned subsidiary of Cable & Wireless plc. Ms. Capitelli holds a CPA license in both Maryland and Virginia. Ms. Capitelli received her Bachelor of Science, Business Administration – Accounting, from Bucknell University.

James E. Goldschmidt, Ph.D. Dr. Goldschmidt joined CASI Pharmaceuticals in April 2016 as Vice President of Business Development. Dr. Goldschmidt brings more than 25 years of experience in the biotechnology and pharmaceutical sectors. Before joining CASI, Dr. Goldschmidt has held positions over the course of more than 25 years including most recently at Macrophage Therapeutics, and prior thereto at ImmuneXcite, TetraLogic Pharmaceuticals, Johnson & Johnson, Wyeth Pharmaceuticals, and SmithKline Beecham. Dr. Goldschmidt is a graduate of Villanova University and went on to receive a master’s degree from Drexel University and a Ph.D. from Temple University School of Medicine.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Kinase Inhibitor Demonstrates Efficacy in a Patient-Derived Xenograft Model of Fibrolamellar Hepatocellular Carcinoma featuring DNAJB1-PRKACA Fusion

Download →

Poster

Evaluation Of ENMD-2076 In Combination With Anti-PD1 In Syngeneic Cancer Models

Download →